Inmed Pharmaceuticals vs Ocugen
Inmed Pharmaceuticals and Ocugen are similar in size: $4.9m and $4.4m of revenue in their latest fiscal years. Ocugen grew faster (8.8% against 7.5%). Inmed Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -34.4% against -1537.4%.
| Latest fiscal year | Inmed PharmaceuticalsINM, 2025 | OcugenOCGN, 2025 |
|---|---|---|
| Revenue | $4.9m | $4.4m |
| Revenue growth | 7.5% | 8.8% |
| Net income | −$1.7m | −$67.8m |
| Operating margin | — | -1425.7% |
| Net margin | -34.4% | -1537.4% |
| Return on equity | -15.0% | — |
| Free cash flow | −$8.1m | −$57.1m |
| Cash | $10.7m | $18.6m |
| Total debt | $0 | $31.5m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 6 | 116 |
| Market value | $9.2m | $253m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 49 buys, 0 sales | 1 buys, 4 sales |